Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden, May 30, 2024. The pharmaceutical company Dicot AB changes its company name to Dicot Pharma AB. The new name was registered by the Swedish Companies Registration Office today, in accordance with the name change decision made at the company's Annual General Meeting on May 6.
Dicot, currently in the clinical phase with its potency drug candidate LIB-01, is in an expansive phase aiming to develop a new generation of potency drugs for a global market. As part of the upgrade to a larger pharmaceutical company, the company's Annual General Meeting on May 6 took the decision to change its name to Dicot Pharma AB.
Today, the name change has been registered by the Swedish Companies Registration Office, formally implementing the change. The company's official website and email addresses will soon transition from dicot.se to dicotpharma.com as part of the ongoing process work of the name change.
The share name will change from Dicot to Dicot Pharma. The last day of trading in the share in the current name is 5 June 2024 and the first day of trading in the new name is 7 June 2024. The short name (ticker) will be unchanged DICOT and the FISN code will be unchanged.
"We are gradually expanding into a larger pharmaceutical company as our results from clinical studies emerge. Strengthening and internationalizing profiling is part of that expansion. The addition "Pharma" is logical and will support us in this process," says Elin Trampe, Dicot Pharma's CEO.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 5,500 shareholders. For more information, please visit www.dicot.se.